drugset / Trial / NCT05414409
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
Phase 2
Recruiting
114 enrolled
Heba M. Ismail
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2026-11-02
- Completion
- 2026-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | — | Oral |